Evidence map›Paper›PMID 25406958›Full record

ArticleBMC neuroscience2014

Chronic escitalopram treatment attenuated the accelerated rapid eye movement sleep transitions after selective rapid eye movement sleep deprivation: a model-based analysis using Markov chains.

Diána Kostyalik, Szilvia Vas, Zita Kátai, Tamás Kitka, István Gyertyán, Gyorgy Bagdy, László Tóthfalusi

Open access · goldAbstract read
In one paragraph

Article in BMC neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Diána KostyalikDepartment of Pharmacodynamics, Semmelweis University, Budapest, Hungary. kostyalik.diana@pharma.semmelweis-univ.hu.
Szilvia VasDepartment of Pharmacodynamics, Semmelweis University, Budapest, Hungary. vas.szilvia@pharma.semmelweis-univ.hu.
Zita KátaiDepartment of Pharmacodynamics, Semmelweis University, Budapest, Hungary. kataizita@gmail.com.
Tamás KitkaDepartment of Neurophysiology, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, Hungary. t.kitka@richter.hu.
István GyertyánDepartment of Behavioural Pharmacology, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, Hungary. i.gyertyan@richter.hu.
Gyorgy BagdyDepartment of Pharmacodynamics, Semmelweis University, Budapest, Hungary. bagdy.gyorgy@pharma.semmelweis-univ.hu.
László TóthfalusiDepartment of Pharmacodynamics, Semmelweis University, Budapest, Hungary. tothfalusi.laszlo@pharma.semmelweis-univ.hu.
Semmelweis University · HUGedeon Richter (Hungary) · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundShortened rapid eye movement (REM) sleep latency and increased REM sleep amount are presumed biological markers of depression. These sleep alterations are also observable in several animal models of depression as well as during the rebound sleep after selective REM sleep deprivation (RD). Furthermore, REM sleep fragmentation is typically associated with stress procedures and anxiety. The selective serotonin reuptake inhibitor (SSRI) antidepressants reduce REM sleep time and increase REM latency after acute dosing in normal condition and even during REM rebound following RD. However, their therapeutic outcome evolves only after weeks of treatment, and the effects of chronic treatment in REM-deprived animals have not been studied yet.

resultsChronic escitalopram- (10 mg/kg/day, osmotic minipump for 24 days) or vehicle-treated rats were subjected to a 3-day-long RD on day 21 using the flower pot procedure or kept in home cage. On day 24, fronto-parietal electroencephalogram, electromyogram and motility were recorded in the first 2 h of the passive phase. The observed sleep patterns were characterized applying standard sleep metrics, by modelling the transitions between sleep phases using Markov chains and by spectral analysis. Based on Markov chain analysis, chronic escitalopram treatment attenuated the REM sleep fragmentation [accelerated transition rates between REM and non-REM (NREM) stages, decreased REM sleep residence time between two transitions] during the rebound sleep. Additionally, the antidepressant avoided the frequent awakenings during the first 30 min of recovery period. The spectral analysis showed that the SSRI prevented the RD-caused elevation in theta (5-9 Hz) power during slow-wave sleep. Conversely, based on the aggregate sleep metrics, escitalopram had only moderate effects and it did not significantly attenuate the REM rebound after RD.

conclusionIn conclusion, chronic SSRI treatment is capable of reducing several effects on sleep which might be the consequence of the sub-chronic stress caused by the flower pot method. These data might support the antidepressant activity of SSRIs, and may allude that investigating the rebound period following the flower pot protocol could be useful to detect antidepressant drug response. Markov analysis is a suitable method to study the sleep pattern.

Indexed as

AnimalsBrainCatheters, IndwellingCitalopramElectrodes, ImplantedElectroencephalographyMaleMarkov ChainsModels, NeurologicalPolysomnographyRandom AllocationRats, WistarSelective Serotonin Reuptake InhibitorsSleep DeprivationSleep, REMTheta RhythmCitalopramSelective Serotonin Reuptake Inhibitors

Identifiers

PMID25406958
PMCPMC4243313
OpenAlexW2082253253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.